SuperGen inks deal to buy Montigen

SuperGen has inked a deal to acquire Salt Lake City-based Montigen for $18 million in cash and stock. Montigen shareholders will also be eligible to earn up to $22 million more based on established regulatory milestones. Montigen has late-stage compounds in its pre-clinical portfolio. These include inhibitors of aurora-A kinase and products which target the tyrosinekinase receptor family. The compounds have shown pre-clinical activity in solid tumors of several cancer types.

- read this article from the UPI